Interaction Between Vasodilators and Vasopressin in Internal Mammary Artery and Clinical Significance.

W Wei,Hs Floten,Gw He
DOI: https://doi.org/10.1016/s0003-4975(01)03322-7
IF: 5.113
2002-01-01
The Annals of Thoracic Surgery
Abstract:Background. Arginine vasopressin (AVP) has recently been demonstrated as an alternative in the treatment of severe refractory vasodilatation in coronary artery bypass grafting. However, AVP may be a spasmogen for graft spasm. We compared the in vitro antispastic effect among calcium-channel antagonists (nifedipine, diltiazem, and verapamil), nitroglycerin, and the highly selective AVP (V1) receptor antagonist [1-deaminopenicillamine, 4-valine, 8-D-arginine] vasopressin.Methods. Human internal mammary artery segments (n = 218) were studied in organ baths. The inhibitory effects of the above vasodilators on AVP-mediated contraction were studied in two ways: relaxation with AVP precontraction and depression of the AVP-induced contraction after pretreatment with vasodilators.Results. All three calcium-channel antagonists caused limited relaxation (18.3% +/- 5.4% for nifedipine, n = 11; 22.2% +/- 3.8% for verapamil, n = 10; and 26.2% +/- 7.5% for diltiazem, n = 9). The plasma concentration of calcium-channel antagonists had no significant depression effect on the AVP-induced contraction. In contrast, [1-deamin-openicillamine, 4-valine, 8-D-arginine] vasopressin caused full (100%, n = 11) and nitroglycerin caused nearly full (93% +/- 3%, n = 10) relaxation. Pretreatment with [1-deaminopenicillamine, 4-valine, B-D-arginine] vasopressin (10(-8), 10(-7), or 10(-6) mol/L, respectively) significantly increased the effective concentration for 50% of the AVP-induced contraction (10(-8.6) +/- 10(0.1) mol/L, p = 0.009; 10(-7.8) +/- 10(0.07) mol/L, p = 0.000; or 10(-6.9) +/- 10(0.11) mol/L, p = 0.000 versus the control, 10(-9.24) +/- 10(0.16) mol/L). However, nitroglycerin only slightly depressed the AVP-induced contraction.Conclusions. [1-Deaminopenicillamine, 4-valine, 8-D-arginine] vasopressin may provide specific antispastic effect in either prophylaxis or treatment of the AVP-related vasospasm in the internal mammary artery. Nitroglycerin may be effective in treatment but has little effect on prophylaxis. Use of calcium-channel antagonists may have little benefit in AVP-related vasospasm.(C) 2002 by The Society of Thoracic Surgeons.
What problem does this paper attempt to address?